Biocryst Pharmaceuticals, Inc. · NASDAQ:BCRX
Biocryst Pharmaceuticals — Q1 2022 Earnings Presentation
8 slides from Biocryst Pharmaceuticals's earnings presentation, May 5, 2022
Slide 1: First Quarter 2022 Results Call
First Quarter 2022 Results Call Corporate Update & Financial Results May 5, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements BioCryst’s presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertain
Slide 3: Agenda
Agenda ◆ Corporate Update: Jon Stonehouse – President and Chief Executive Officer ◆ ORLADEYO® (berotralstat) Launch Update: Charlie Gayer – Chief Commercial Officer ◆ BCX9930 Investigation Update Dr. Bill Sheridan– Chief Medical Officer ◆ Financial Update Anthony Doyle – Chief Financial Officer ◆ Su
Slide 4: Current BCX9930 Clinical Trials
Current BCX9930 Clinical Trials ◆ REDEEM-1 • Randomized, open-label, active, comparator-controlled comparison of the efficacy and safety of BCX9930 at 500 mg bid monotherapy in patients with an inadequate response to a C5 inhibitor ◆ REDEEM-2 • Randomized, placebo-controlled trial to evaluate the ef
Slide 5: Summary of Current Status of BCX9930 Investigation
Summary of Current Status of BCX9930 Investigation ◆ Three patients with PNH enrolled in the randomized REDEEM trials had early onset, and moderate or severe, increased serum creatinine (2-4 xULN) after several weeks of dosing with 500 mg twice-daily • All 3 patients in the REDEEM trials with increa
Slide 6: Key Efficacy Parameters for 400 mg bid and 500 mg bid in Proof-of-Concept Long-term Extension Study
Key Efficacy Parameters for 400 mg bid and 500 mg bid in Proof-of-Concept Long-term Extension Study Support Similar Efficacy at Both Dose Levels Parameter 400 mg bid period 500 mg bid period N subjects (treatment naïve) 7 7 Duration of Treatment, days 134 (109) 445 (130) RBC Transfusions, (n) 0 0 La
Slide 7: Cash Position (in millions)
Cash Position (in millions) Cash, cash equivalents, restricted cash & investments at March 31, 2021 $244 Cash, cash equivalents, restricted cash & investments at March 31, 2022 $447 Senior credit facility A $146 FY 2022 GUIDANCE ORLADEYO Revenue > $250 Operating expenses B $440 - $480 A – From Athyr
Slide 8: First Quarter 2022 Results Call
First Quarter 2022 Results Call Corporate Update & Financial Results May 5, 2022
BioCryst Pharmaceuticals — Q1 2022 Earnings Presentation on 6ix